EQT Ventures, a private equity firm, led a $20m Series A financing in Insempra, a biotechnology company, with participation from BlueYard Capital, Possible Ventures, Taavet Sten, Acequia Capital, Henkel dx Ventures, Bayern Kapital and Alante Capital. “We are grateful for the support of this group of investors who have recognized the potential of Insempra’s market-first approach and innovative technology platforms. Working in collaboration with nature, we will continue to expand our capacity to develop intrinsically sustainable materials that are superior in quality and will reduce our dependency on chemical industrialization processes,” Jens Klein, Insempra Founder and CEO.